Europe Alzheimer Drug Pipeline Analysis

Publish Date:- Jan-2014       No Of Pages (265)

Electronic Access - Single User License $1500 Buy Now
CD-ROM Mail Delivery $1800Buy Now
Hard Copy Mail Delivery $2400 Buy Now
Electronic Access - Multi-User License $3000 Buy Now


The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure on the social and health-care systems of the region. There is an urgent need for developing curative or disease-modifying therapies to offset the upcoming Alzheimer’s disease epidemic.

Europe Alzheimer’s Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “Europe Alzheimer’s Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Europe Alzheimer’s Disease Drug Pipeline by Clinical Phase:

• Research: 19

• Preclinical: 49

• Clinical: 1

• Phase-I: 25

• Phase-I/II: 2

• Phase-II: 26

• Phase-II/III: 2

• Phase-III: 5

• Preregistration: 2

• Marketed: 10

• Unknown: 1


The incidence of Alzheimer’s disease has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been observed that close to 50% of dependency of aged people in Europe is attributed for by Alzheimer’s disease. The rapid growth in the prevalence of Alzheimer's disease over the next few decades in Europe is expected to result in immense pressure on the social and health-care systems of the region. There is an urgent need for developing curative or disease-modifying therapies to offset the upcoming Alzheimer’s disease epidemic.

Europe Alzheimer’s Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drugs being developed for the treatment of Alzheimer disease. Research report covers all the ongoing drugs being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Alzheimer drug market based upon development process.

Following parameters for each drug profile in development phase are covered in “Europe Alzheimer’s Drug Pipeline Analysis” research report:

• Drug Profile Overview

• Alternate Names for Drug

• Active Indication

• Phase of Development

• Mechanism of Action

• Brand Name

• Patent Information

• Country for Clinical Trial

• Owner / Originator/ Licensee/Collaborator

• Administrative Route

• Drug Class

• ATC Codes



Europe Alzheimer’s Disease Drug Pipeline by Clinical Phase:

• Research: 19

• Preclinical: 49

• Clinical: 1

• Phase-I: 25

• Phase-I/II: 2

• Phase-II: 26

• Phase-II/III: 2

• Phase-III: 5

• Preregistration: 2

• Marketed: 10

• Unknown: 1

1. Europe Alzheimer’s Disease Market Overview



2. Alzheimer’s Disease Drug Clinical Phase: Unknown

  2.1 Overview

  2.2 Alzheimer’s Disease Drug Profile in Clinical Phase



3. Alzheimer’s Disease Drug Clinical Phase: Research

  3.1 Overview

  3.2 Alzheimer’s Disease Drug Profile in Clinical Phase



4. Alzheimer’s Disease Drug Clinical Phase: Preclinical

  4.1 Overview

  4.2 Alzheimer’s Disease Drug Profile in Clinical Phase



5. Alzheimer’s Disease Drug Clinical Phase: Clinical

  5.1 Overview

  5.2 Alzheimer’s Disease Drug Profile in Clinical Phase



6. Alzheimer’s Disease Drug Clinical Phase: Phase-I

  6.1 Overview

  6.2 Alzheimer’s Disease Drug Profile in Clinical Phase



7. Alzheimer’s Disease Drug Clinical Phase: Phase-I/II

  7.1 Overview

  7.2 Alzheimer’s Disease Drug Profile in Clinical Phase



8. Alzheimer’s Disease Drug Clinical Phase: Phase-II

  8.1 Overview

  8.2 Alzheimer’s Disease Drug Profile in Clinical Phase



9. Alzheimer’s Disease Drug Clinical Phase: Phase-II/III

  9.1 Overview

  9.2 Alzheimer’s Disease Drug Profile in Clinical Phase



10. Alzheimer’s Disease Drug Clinical Phase: Phase-III

  10.1 Overview

  10.2 Alzheimer’s Disease Drug Profile in Clinical Phase



11. Alzheimer’s Disease Drug Clinical Phase: Preregistration

  11.1 Overview

  11.2 Alzheimer’s Disease Drug Profile in Clinical Phase



12. Marketed

  12.1 Overview

  12.2 Marketed Drug Profile


Each Drug Profile has Tables Representing Following Information:

• Alternate Names

• Originator & Owner

• Collaborator

• Technology Provider

• Licensee

• Highest Development Phase

• Indications

• Class

• Mechanism of Action

• ATC Code

• Designated Brand Name